leadXpro, FIRST TENANT OF PARK INNOVAARE’S NEW INNOVATION CAMPUS
Construction of the 23,000m2 new campus has begun. One month after the groundbreaking ceremony, leadXpro is the first company to ascertain its position...
More details More detailsInterAx partners with Lundbeck to identify better pharmaceutical compounds
InterAx Biotech AG, a spin-off of the Paul Scherrer Institute PSI and ETH Zurich, based at PARK INNOVAARE, is building a proprietary systems biology platform...
More detailsVilligen – Boston – Villigen: Successful Business Trip for InterAx Biotech AG
InterAx Biotech AG participated in a “business boosting” week in Boston, USA, in June, 2016. As part of venturelab’s international program, 10 high...
More detailsSwissUpStart Challenge accepted, SwissUpStart Challenge completed! InterAx Biotech won the first prize.
With their biosensors, pharmaceutical industry can save 100 million CHF in the development of new drugs. No wonder the newly born spin-off of the Paul...
More detailsInterAx Biotech AG is strengthening its scientific advisory board
Scientific advisory boards set the bar for the quality of research and development performed in big pharma, medium biotech and small start-ups. Their excellence...
More detailsInterAx Biotech has started a new collaboration
Collaborations speed up innovation. InterAx Biotech AG, a spin-off of the Paul Scherrer Institute (PSI) and ETH Zurich, based at PARK INNOVAARE, and Professor...
More detailsShaping the future of modern drug discovery
Video interview with Professor Dr. Gebhard Schertler Pharmaceutical and biotechnological industries often depend on the information acquired through...
More detailsThe value of the absolute structure
The exact knowledge and understanding of a molecule’s structure underpin all the substantial progress in chemical, agrarian and pharmaceutical research....
More detailsUnprecedented speed and success rate with delivering ligand-bound GPCR structures
Modern drug discovery greatly benefits from knowledge of how a drug interacts with its molecular drug target. Membrane protein drug targets represent a...
More detailsState-of-the-art bioinformatics for better drug discovery
The effect a drug has on the human body depends on how well its active substance find its way to the targeted cells in the body, and on the chemical reactions...
More detailsBiosensors Technology Platform for efficient lead discovery
In April 2016, the team at InterAx Biotech AG mounted the nameplate of a newly-born company on the wall of PARK INNOVAARE’s deliveryLAB, thus giving...
More details